Study Finds Imprimis’ Dropless Compounds Safe for Use in Cataract Surgery with Trabecular Microbypass Stents

June 1, 2018: By Jon Swedien

A recent study found Imprimis Pharmaceuticals’ Dropless formulations might be a safe option for glaucomatous eyes having cataract surgery with trabecular microbypass stent insertion, the San Diego company announced May 30.

The Imprimis Dropless formula is a single intraocular injection of triamcinolone and moxifloxacin (Tri-Moxi) or triamcinolone, moxifloxacin, and vancomycin (Tri-Moxi-Vanc).

Both formulations are designed to be administered during ocular surgery to replace or reduce the need for patient-administered antibiotic and anti-inflammation drops after surgery.

The Journal of Cataract and Refractive Surgery in January 2018 published a study of 483 eyes with glaucoma comparing the Dropless formulations with a standard drop regimen following surgery.

The study found that the Dropless formulations were similar to a standard drop regimen in terms of safety.

Imprimis CEO Mark Baum said the advantage of Dropless is doctors and patients don’t have to worry about a drop regime after surgery.

“This formulation continues to be an important option for patients and doctors alike, to help reduce or eliminate the need for post-surgery eye drop regimens and the potential for complications with medication adherence,” Baum said.

The study participants were diagnosed with primary open-angle glaucoma and received a glaucoma stent at the time of their cataract surgery.

To evaluate safety, the study recorded incidence of intraocular pressure (IOP) spikes, defined as an increase of at least 15 mmHg from baseline IOP. There was no statistically significant difference in the rate of IOP spikes between the two groups.

The safety profiles of both groups were also favorable. In the study group, there were no reported cases of inflammation, cystoid macular edema (CME), infection, or retinal detachments.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT